NIVO in PAP
02 Dec 2020
Trial Summary
This study is to capture and describe the patient and disease characteristics and the outcomes of adult patients with previously-treated advanced NSCLC who have been treated with Nivolumab
Acronym:
NIVO PAP
ACTRN/NCT /ethics:
NCT03804554
Scientific title:
Nivolumab in the Treatment of Patients With Non-small Cell Lung Cancer: The Australian Experience
Sponsor / Cooperative group:
Bristol-Myers Squibb
Trial & Patient Characteristics
| Cancer Type | Lung & mesothelioma |
|---|---|
| Trial Type | Early detection, diagnosis, prognosis |
| Phase | All phases |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | Non-small Cell Lung Cancer |
| Cancer Stage | All stages |
| Anticipated Start Date | 2018-10-03 |
| Anticipated End Date | 2020-12-01 |
Participating Hospitals
| Hospital | Royal Adelaide Hospital |
|---|---|
| Clinical Trial Coordinator | Anne Milton |
| anne.milton@sa.gov.au | |
| Phone | 08 7074 2342 |
| Principal Investigator | Professor Michael Brown |
| Recruitment Status | Recruiting |